Kanika Jain
Kanika Jain has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Andre M. Oliveira
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
69 shared publications - Gerd A. Blobel
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
69 shared publications - Ian C. Henrich
Merlin Biotech/Baruch S. Blumberg Institute, Philadelphia, Pennsylvania
69 shared publications - Laura Quick
Department Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
69 shared publications - Margaret M. Chou
Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia and the Perelman School of Medicine, Philadelphia, PA 19104, USA
69 shared publications - Robert Young
Department Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
69 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supp Fig S9 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
USP6 mRNA triggers immunostimulatory effects in diverse cancer types
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Fig S9 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
USP6 mRNA triggers immunostimulatory effects in diverse cancer types
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supp Fig S3 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
IVT USP6 mRNA recapitulates immunostimulatory effects
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Fig S3 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
IVT USP6 mRNA recapitulates immunostimulatory effects
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supp Fig S6 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
Kaplan Meier of Additional Cancers
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Fig S6 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
Kaplan Meier of Additional Cancers
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supp Fig S1 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
Cytotoxix Effects of USP6 mRNA via IFN-TRAIL
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Fig S1 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
Cytotoxix Effects of USP6 mRNA via IFN-TRAIL
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supp Fig S4 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
Immune markers in co-cultured PBMCs
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Fig S4 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
Immune markers in co-cultured PBMCs
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supp Fig S8 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
USP6 mRNA triggers immunostimulatory effects in head and neck cancer
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Fig S8 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
USP6 mRNA triggers immunostimulatory effects in head and neck cancer
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supp Fig S10 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
Summary of anti-tumorigenic mechanism of USP6 mRNA LNPs
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Fig S10 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
Summary of anti-tumorigenic mechanism of USP6 mRNA LNPs
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supp Fig S2 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
Summary of immunostimulatory effects of USP6
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Fig S2 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
Summary of immunostimulatory effects of USP6
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supp Fig S7 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
USP6 mRNA effects in AML xenografts
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Fig S7 from Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
USP6 mRNA effects in AML xenografts